secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001193125-25-289768
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IKT advances IKT-001 to global pivotal Phase 3 in PAH; ATM prospectus terminated
--------------------------------------------------------------------------------

- IMPROVE-PAH Phase 3 trial for IKT-001 in pulmonary arterial hypertension expected to start Q1 2026 across up to 180 sites.
- Adaptive two-part design: Part A (140 pts, primary endpoint PVR at Week 24) and Part B (346 pts, primary endpoint 6MWD at Week 24).
- Prior Phase 2b plan replaced after FDA Type C meeting; company cites advantages of uninterrupted enrollment and dose titration.
- ATM prospectus terminated with no sales made; Sales Agreement with Jefferies remains in effect without further sales pending new filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525289768/0001193125-25-289768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525289768/d20255d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-289768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer